PHGE
$4.89-0.09 (-1.81%)
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage...
Recent News
BiomX announces $3M private placement
BiomX (PHGE) entered into definitive agreements in connection with a private investment in public equity financing for expected gross proceeds of approximately $3M, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. In the Private Placement, the Company agreed to issue and sell shares of its Series Y Convertible Preferred Stock, with a stated value of $1,000 per share, together with warrants w
All You Need to Know About BiomX (PHGE) Rating Upgrade to Buy
BiomX (PHGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sector Update: Health Care Stocks Fall Late Afternoon
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the
Top Midday Decliners
Meihua International Medical Technologies (MHUA) shares plunged 43% after the company reported late
BiomX Inc (PHGE) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
BiomX Inc (PHGE) progresses in clinical trials for BX004 and BX011, despite facing financial constraints and a temporary FDA hold on US trials.